Source: Annual Congress 2002 - Thoracic oncology: clinical management
Disease area: Thoracic oncology

Abstract

Purpose: Optimal combination of anticancer agents with radiation are not established, although chemoradiotherapy is a standard treatment for stage III NSCLC. The combination of paclitaxel and carboplatin is one of the standard regimens for the treatment of advanced NSCLC, and both paclitaxel and carboplatin are reported to have radiation-enhancing properties. Thus, we have conducted a multi-institutional phase II trial with concurrent use of paclitaxel and carboplatin plus thoracic radiation for locally advanced NCCLC.Methods: Patients were treated with the following regimen: paclitaxel (45 mg/m2) and carboplatin (AUC = 2) were administered every 7 days for 10 week. When PR was observed, chemotherapy is extended upto 16 weeks. Radiation therapy were administered 1.8~2.0 Gy/day for 5~7 week (total 60~65 Gy).Results: So far, 34 patients were enrolled, and 27 patients were analyzed for the toxicity and efficacy. The hematologic toxicities were grade 3 leukopenia (7.4%), grade 4 thrombocytopenia (3.7%), grade 3 anemia (14.8%). However, there were 3 cases with treatment related death. One patient died of pulmonary toxicity, one with hemorrhage due to radiation necrosis, and one with infection which occurred after the recovery from hematologic toxicity. The response rate was 78% with 1 CR and 17 PR.Conclusion: Concurrent use of radiation and paclitaxel plus carboplatin appeared to be active and promising regimen to stage III NSCLC. However, careful clinical follow-up is required to confirm the safety and efficacy of this regimen. Updated data is to be presented.

Rating:

Share or cite this content

Citations should be made in the following way:
Y. Horiuchi, M. Kawasaki, H. Yamasaki, K. Ninomiya, S. Takeo, S. Hayashi, T. Ohshima, M. Kuba, Y. Nakanishi, N. Hara (Fukuoka, Japan). Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial. Eur Respir J 2002; 20: Suppl. 38, 1190

Member's Comments

No comment yet.

Related content which might interest you: Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 12s Year: 2005 Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020 A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006